Divisadero Street Capital Management LP Invests $2.01 Million in Indivior PLC $INDV

Divisadero Street Capital Management LP acquired a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 136,000 shares of the company’s stock, valued at approximately $2,005,000.

Several other large investors also recently modified their holdings of INDV. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Indivior by 16.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the period. Y Intercept Hong Kong Ltd lifted its position in shares of Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock valued at $375,000 after acquiring an additional 3,769 shares in the last quarter. Amalgamated Bank bought a new position in Indivior in the 2nd quarter worth approximately $61,000. CTC Alternative Strategies Ltd. purchased a new position in Indivior during the first quarter valued at $96,000. Finally, Prudential Financial Inc. purchased a new position in shares of Indivior during the second quarter valued at about $207,000. Institutional investors own 60.33% of the company’s stock.

Analysts Set New Price Targets

INDV has been the topic of a number of research reports. Craig Hallum restated a “buy” rating and issued a $41.00 target price on shares of Indivior in a report on Friday, October 31st. Northland Securities set a $40.00 price target on shares of Indivior in a research note on Friday, October 31st. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. HC Wainwright upped their target price on Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $32.71.

Indivior Price Performance

Shares of NASDAQ INDV opened at $35.12 on Monday. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $35.31. The business has a 50-day simple moving average of $28.55 and a two-hundred day simple moving average of $22.05.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to analyst estimates of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. As a group, equities research analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.